Creative Medical Technology announced the successful receipt of orphan drug designation from the FDA for CELZ-101, ImmCelz. This therapy is aimed at preventing allograft rejection in patients undergoing pancreatic islet cell transplantation, a significant advancement for individuals dealing with brittle Type 1 diabetes, a condition characterized by extreme fluctuations in blood glucose levels.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
